Cancer Discov (2026) 16 (10): OF1.
Pancreas Center, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, ...
AbstractCDK12 mutations occur in 2% to 7% of metastatic prostate cancers (mPCa) and are considered to be exclusively somatic. In this study, we identified five patients with mPCa (ages 44ā62) ...
Abstract. Neoadjuvant chemoimmunotherapy improves outcomes in resectable nonāsmall cell lung cancer, yet pathologic response incompletely predicts durability of benefit. Spatial profiling using ...
Split-Screen Open the PDF for AACR Cancer Progress Report 2026AACR Cancer Progress Report 2026 in another window Share Tools ...
AbstractThe immune system can eradicate cancer, but various immunosuppressive mechanisms active within a tumor curb this beneficial response. However, unraveling the effects of multimodal interactions ...
AbstractImmune checkpoint blockade (ICB) has revolutionized cancer treatment, yet its efficacy in gastrointestinal malignancies is often limited by an immunosuppressive tumor microenvironment. In this ...
Abstract. Clonal hematopoiesis of indeterminate potential (CHIP) is a precursor condition characterized by the expansion of mutant hematopoietic stem and progenitor cell (HSPC) clones that increases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results